Company intelligence / Profile preview

AyuVis Research, Inc.

Fort Worth, Texas, United Statesayuvis.com ↗

Ownership: Private
Development stage: Other

Overview

AyuVis received FDA clearance for its AVR-48 IND application in January 2024 and is proceeding with a Phase 1 clinical trial. The Phase 1 will be a double-blinded, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate safety and tolerability in healthy adult volunteers. Pre-clinical research has shown that AVR-48 can prevent inflammation and tissue damage, promote new lung cell growth, quiet cytokine storms, and remain effective against multi-drug resistant infections[7].

Therapeutic areas: GastroenterologyPulmonologyNephrologyOphthalmologyImmunologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

AVR-48

4 more assets in the full pipeline.

Partnerships

Strategic discussions with large pharmaceutical companies are in progress[3]

Beyond the preview

Go deeper on AyuVis Research, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AyuVis Research, Inc..